

## SLNo 6 Profit(Loss) for the Period from Continuing Operations Profit(Loss) from Discontinuing Operations Tax Expenses on discontinuing Operations Expenses (a) Cost of Material Consumed (b) Purchase of stock-in-trade (c) Changes in Inventories of finished goods, work-in-progress and stock-in-trade Tax Expenses Add(+)/Less(-) Exceptional items Profit before exceptional items and Tax (f) Depreciation and Amortisation expense (g) Other Expenses Total Expenses Profit before Tax Total income (a) Revenue From Operations (b) Other Income (e) Finance Cost (d) Employee benefit expense Income Particulars Unaudited 30-09-2017 3 months ended 519.19 156.83 62.51 52.59 212.50 11.23 530.42 509.36 21.06 34.76 11.23 8.55 2.68 Preceding 3 months 30-06-2017 Unaudited ended 93.60 25.85 37.65 349.81 532.42 516.51 19.44 535.95 2.32 3.53 3.53 1.21 Correspondin g 3 months ended in the previous year 30-09-2016 Unaudited 47.13 32.04 29.08 287.50 399.51 15.47 414.98 407.78 7.20 11.85 15.47 3.62 Current Year ended in the Unaudited 30-09-2017 Half Year 1,051.61 1,066.37 1,025.87 40.50 562.31 250.43 88.36 90.24 60.27 14.76 10.87 14.76 3.89 Previous Year ended in the Unaudited 30-09-2016 Half Year 840.13 605.05 28.92 869.05 852.29 16.76 21.78 56.57 99.54 69.57 28.92 9.40 Previous Year ended 31-03-2017 Audited 1,766.67 1,269.02 1,878.89 1821.72 57.17 99.01 -13.21 88.27 112.22 122.51 131,53 227.76 15.85 10.74

Registered Office:Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Hyderabad-500008. CONSOLIDATED UN AUDITED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30TH SEPTEMBER'2017 JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Rupees inlakhs

		18			17			16	15	14	13	A .					12	11	I
b) Diluted	a) Basic	Earnings per Equity share ( for Continuing & discontinued operations)	b) Diluted	a) Basic	Earnings per Equity share ( for discontinued operations)	b) Diluted	a) Basic	Earnings per Equity share ( for continuing operations)	Other equity excluding revaluation reserve	Paid Up Equity Share Capital (Face Value of Rs.10/- each)	Total Comprehensive Income for the period		(ii) Income tax relating to items that will be reclassified to profit or loss	B (i) Items that will be reclassified to profit or loss	(ii) Income tax relating to items that will not be reclassified to profit or loss	A (i) Items that will not be reclassifed to profit or loss	Other Comprehensive Income	Profit(Loss) for the period	
0.09	0.09					0.09	0.09			927.95	8.55					•		8.55	
0.03	0.03					0.03	0.03			927.95	2.32							2.32	
0.20	0.20					0.20	0.20			604.16	11.85			ı				11.85	
0.12	0.12					0.12	0.12		783.18	927.95	10.87							10.87	
0.36	0.36					0.36	0.36		(425.89)	604.16	21.78			1				21.78	
0.95	0.95					0.95	0.95		772.31	927.95	88.27		,	,				88.27	

Notes to the Consolidated Unaudited Financial Results

- Transition to Ind-AS:
- results as at 1st April 2016 and accordingly figures have been restated in all the subsequent periods. The company has adopted Ind AS with effect from 1st April 2017 and accordingly the comparatives are restated. Accordingly the impact of transition has been provided in the opening
- quarter ended 30th September 2016, half year ended 30th September 2016 and previous year ended 31st March 2017, have been restated to comply with Ind AS to make them comparable. Results for the quarter/half year ended 30th September 2017 are in compliance with Indan Accounting Standards notified by the Ministry of Corporate Affairs. Consequently result for the
- The above results have been reviewed by the Audit Committee at its meeting held on 14.12.2017 and approved by the Board of Directors of the Company at its meeting held on 14.12.2017 The results have been subjected to limited review by the statutory auditors.
- figures for the first quarter ended 30th June 2017. The figures for the quarter ended 30th September 2017 are balancing figures between unaudited figures in respect of 6 months period ended 30th September 2017 and published year to date
- effect from 01-July-2017. The Group currently has two segments (i) clinical research services and (ii) Information technology services. The Company has discontinued the Data management services division with
- Figures have been rearranged whereever necessary.
- Provision for Deffered tax will be provided at the end of the year.
- The above consolidated financial results include the Unaudited financial results of the wholly owned subsidiaries, M/s Enhops Solutions Pvt Ltd & Enhops Inc.

Place:Hyderabad Date: 14.12.2017



## SEGMENT-WISE REVENUE, RESULTS & CAPITAL EMPLOYED (Consolidated Unaudited) UNDER CLAUSE 41 OF THE LISTING AGREEMENT FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2017

			The same of the			Kupees makins
Particulars	3 months ended	Preceding 3 months ended	g 3 months ended in the	Half Year ended in the Current Year	Half Year ended in the Previous Year	Previous Year ended
	30-09-2017	30-06-2017	30-09-2016	30-09-2017	30-09-2016	31-03-2017
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
SEGMENT REVENUE: (Net Sales / Income from Operations)						
a) Clinical Research Services	483.23	303.40	60.54	786.63	153.96	347.09
b) Information Technology Services	26.13	13.93	41.56	40.06	56.96	194.28
c) Data Management Services	0.00	199.18	305.68	199.18	641.37	1,28
d) Unallocable income	21.06	19.44	7.20	40.50	16.76	57.17
Total:	530.42	535.95	414.98	1,066.37	869.05	1,878.88
LESS: Inter Segment revenue		1	•			
Net Sales/income from Operations.	530.42	535.95	414.98	1,066.37	869.05	1,878.88
SEGMENT RESULTS: PROFIT / (LOSS) BEFORE TAX AND INTEREST						
a) Clinical Research Services	41.96	5.75	41.21	47.71	-65.32	-1:
b) Information Technology Services	1.33	-1.47	18.11	-0.14	13.06	6
c) Data Management Services		5.66	63.41	5.66	133.99	258.56
LESS: Total:	43.29	9.94	40.31	53.23	81.73	19
i) Interest	53.12	25.85	32.04	78.97	69.57	131.53
ii) Other Un-Allocable Expenditure	0		•			21.60
iii) Un-Allocable Income	-21.06	-19.44	-7.20	-40.50	-16.76	-57.17
TOTAL PROFIT /(-LOSS) BEFORE TAX	11.23	3.53	15.47	14.76	28.92	99.01

NOTES:

i) Segment Capital Employed: Fixed Assets used in the Company's business have been identified and only computers, software and work stations are shared among different segments.

Place:Hyderabad Date: 14.12.2017

for Jeevan Scientific Technology Limited On behalf of the Board of Directors

K. Krishna Kishore Vice Chairman & Managing Director



## STATEMENT OF ASSETS & LIABILITIES AS AT 30TH SEPTEMBER 2017

(Rs.in Lakhs)

Stand A	Alone		Consolidated				
As At 30.09.2017 (Un Audited)	As at 31.03.2017 (Audited)	Particulars	As At 30.09.2017 (Un Audited)	As at 31.03.2017 (Audited)			
		Assets					
		(1)Non-current Assets					
1752.17	1052.30	7	1759.94	1062.33			
69.59	46.59	b) Other Intangible Assets	74.08	50.66			
353.96	284.12	<ul> <li>c) Intangible Assets under Development</li> <li>d) Financial Assets</li> </ul>	707.78	522.03			
52.69	52.69	i)Investments					
336.25	243.26	ii)Loans					
58.05	58.14	iii) Advances	58.05	58.13			
12.82	12.82	c) Deferred tax asset (net) (2)Current Assets	11.71	11.7			
50.00	47.41	a) Inventories b) Financial Assets	50.00	47.42			
1427.66	1110.69	i) Trade receivables	1453.42	1132.52			
25.22	19.69	ii) Cash and cash equivalents	26.85	25.7			
40.69	47.70	iii)Loans	40.69	49.43			
153.50	135.52	c) Other Current Assets	163.25	141.85			
4332.60	3110.93	TOTAL ASSETS	4345.77	3101.81			
		Equity and Liabilities Equity					
927.95	927.95	a) Equity Share Capital	927.95	927.95			
844.32	827.80	b) Other Equity	783.18	772.31			
		Liabilities					
		(1)Non-current Liabilities a) Financial liabilities					
1343.94	474.75	Borrowings	1343.94	474.7			
11.08	7.47	b) Provisions (2)Current Liabilities a)Financial Liabilities	11.08	7.47			
364.00	246.22	i) Borrowings	373.86	246.22			
95.04	166.46	ii) Trade Payables	95.04	166.4			
118.24	124.29		141.36	139.6			
554.92	264.89	b) Other current liabilities	572.04	277.8			
73.11	71.10	c) Provisions	97.32	89.21			
4332.60	3110.93	TOTAL EQUITY & LIABILITIES	4345.77	3101.81			

